Abstract
Usage of excipients from natural sources is now the most attractive research areas. Most of the synthetic polymers used in the formulation are detrimental to some extent for the human physiological system. Herbal substitute will be the best choice to minimize long term adverse effect. The purposes of repeated dose toxicity testing are to obtain information about biologic activity of chemicals. In the present study, repeated oral toxicity study of formulation containing metformin 1000mg and sitagliptin 50mg in Swiss albino rats was studied. Microwave assisted acrylamide grafted C. tora is used as a polymer in the formulation.
Rats of both sexes from control and different dose groups (100, 200 and 400 mg/Kg body wt.) exhibited normal body weight gain throughout dosing period. Study protocol was prior approved by animal ethics committee. Combination treatment for 28 days, formulation did not show any significant features of haematological, behavioural, hepatotoxicity and nephrotoxicity in rats. Therefore it can be concluded that the combination using the grafted polymer is safe in these repeated doses in rats.
Keywords: Metformin, sitagliptin, toxicity, Grafted Cassia tora, swiss albino rats.
Graphical Abstract
The Natural Products Journal
Title:Repeated dose Toxicity Study in Rats of the Formulation Containing Metformin and Sitagliptin using Microwave Assisted Acrylamide Grafted Cassia tora as Polymer
Volume: 6 Issue: 2
Author(s): Shubhasis Dan, Nilendra Chatterjee, Pallab Mandal, Anjan Das, Balaram Ghosh and Tapan Kumar Pal
Affiliation:
Keywords: Metformin, sitagliptin, toxicity, Grafted Cassia tora, swiss albino rats.
Abstract: Usage of excipients from natural sources is now the most attractive research areas. Most of the synthetic polymers used in the formulation are detrimental to some extent for the human physiological system. Herbal substitute will be the best choice to minimize long term adverse effect. The purposes of repeated dose toxicity testing are to obtain information about biologic activity of chemicals. In the present study, repeated oral toxicity study of formulation containing metformin 1000mg and sitagliptin 50mg in Swiss albino rats was studied. Microwave assisted acrylamide grafted C. tora is used as a polymer in the formulation.
Rats of both sexes from control and different dose groups (100, 200 and 400 mg/Kg body wt.) exhibited normal body weight gain throughout dosing period. Study protocol was prior approved by animal ethics committee. Combination treatment for 28 days, formulation did not show any significant features of haematological, behavioural, hepatotoxicity and nephrotoxicity in rats. Therefore it can be concluded that the combination using the grafted polymer is safe in these repeated doses in rats.
Export Options
About this article
Cite this article as:
Dan Shubhasis, Chatterjee Nilendra, Mandal Pallab, Das Anjan, Ghosh Balaram and Kumar Pal Tapan, Repeated dose Toxicity Study in Rats of the Formulation Containing Metformin and Sitagliptin using Microwave Assisted Acrylamide Grafted Cassia tora as Polymer, The Natural Products Journal 2016; 6 (2) . https://dx.doi.org/10.2174/2210315506666160503163018
DOI https://dx.doi.org/10.2174/2210315506666160503163018 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Targeted Tumor Therapies at a Glance
Current Drug Targets Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery